Clinical significance of drug-drug interactions during HCV therapy with sofosbuvir and simeprevir in comparison to first wave protease inhibitors

Background: Recently, it has been shown that considerable drug-drug interactions (DDI) between a first wave protease inhibitor (PI, boceprevir or telaprevir) and the regular outpatient medication affect up to 50% of hepatitis C virus (HCV) infected patients. The lately approved second wave direct-acting antiviral agents (DAA) sofosbuvir (SOF) and simeprevir (SMV) are supposed to be involved in less DDI. However, so far, no data is available regarding the potential benefit in the real-world. We here aimed to evaluate the risk for DDI with the regular outpatient medication during therapy with SOF and SMV in compar…